Top

Published in:

Open Access 01-04-2020 | Literatur kommentiert

Frühe Salvage-Bestrahlung der Prostataloge scheint gleichwertig zu sein mit der direkten adjuvanten Bestrahlung bei Prostatakrebspatienten nach radikaler Prostatektomie

Authors: Dr. med. M. Shelan, Prof. Dr. med. D. Aebersold, Prof. Dr. med. P. Ghadjar

Published in: Strahlentherapie und Onkologie | Issue 4/2020

Auszug

Die direkt postoperative (adjuvante) Radiotherapie der Prostataloge bei postoperativem PSA (prostataspezifisches Antigen) im Nullbereich, aber vorhandenen Risikofaktoren wie R1 und/oder T3 ist zur Verbesserung der biochemischen Kontrolle eine evidenzgesicherte Behandlungsoption beim lokalisierten Prostatakarzinom nach radikaler Prostatektomie [1‐3]. Allerdings bekommt nicht jeder Patient mit Risikofaktoren ohne adjuvante Radiotherapie ein PSA-Rezidiv, sodass die adjuvante Radiotherapie zumindest in manchen Fällen eine Übertherapie darstellt. An vielen Zentren wird heutzutage daher die frühe Salvage-Radiotherapie der Prostataloge bei Patienten mit PSA-Rezidiv favorisiert [4]. …

Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–962. https://doi.org/10.1016/j.juro.2008.11.032 CrossRefPubMedPubMedCentral

Bolla M, Van Poppel H, Collette L et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578CrossRef

Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J Clin Oncol 27(18):2924–2930. https://doi.org/10.1200/JCO.2008.18.9563 CrossRefPubMed

Stephenson AJ, Scardino PT, Kattan MW et al (2009) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041. https://doi.org/10.1200/JCO.2006.08.9607 CrossRef

Gandaglia G, Briganti A, Clarke N et al (2017) Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients[figure presented. Eur Urol 72(5):689–709. https://doi.org/10.1016/j.eururo.2017.01.039 CrossRefPubMed

Hwang WL, Tendulkar RD, Niemierko A et al (2018) Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol 4(5):1–8. https://doi.org/10.1001/jamaoncol.2017.5230 CrossRef

Abdollah F, Dalela D, Sood A et al (2018) Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection. Eur Urol 74(3):253–256. https://doi.org/10.1016/j.eururo.2018.04.017 CrossRefPubMed

Briganti A, Karnes RJ, Da Pozzo LF et al (2011) Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2–4 pN+ prostate cancer: results of a matched analysis. Eur Urol 59(5):832–840. https://doi.org/10.1016/j.eururo.2011.02.024 CrossRefPubMed

Wiegel T, Bartkowiak D, Bottke D et al (2015) Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys 91(2):288–294. https://doi.org/10.1016/j.ijrobp.2014.09.039 CrossRefPubMed

10.

Van Der Kwast TH, Bolla M, Van Poppel H et al (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25(27):4178–4186. https://doi.org/10.1200/JCO.2006.10.4067 CrossRef

11.

Bottke D, Golz R, Störkel S et al (2013) Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: Impact of pathology review on analysis. Eur Urol 64(2):193–198. https://doi.org/10.1016/j.eururo.2013.03.029 CrossRefPubMed

12.

Abdollah F, Suardi N, Cozzarini C et al (2013) Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 63(6):998–1008. https://doi.org/10.1016/j.eururo.2012.10.036 CrossRefPubMed

13.

Zhao SG, Chang SL, Spratt DE et al (2016) Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol 17(11):1612–1620. https://doi.org/10.1016/S1470-2045(16)30491-0 CrossRefPubMed

14.

Den RB, Yousefi K, Trabulsi EJ et al (2015) Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 33(8):944–951. https://doi.org/10.1200/JCO.2014.59.0026 CrossRefPubMedPubMedCentral

15.

Ross AE, Den RB, Yousefi K et al (2016) Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis 19(3):277–282. https://doi.org/10.1038/pcan.2016.15 CrossRefPubMedPubMedCentral

Title: Frühe Salvage-Bestrahlung der Prostataloge scheint gleichwertig zu sein mit der direkten adjuvanten Bestrahlung bei Prostatakrebspatienten nach radikaler Prostatektomie
Authors: Dr. med. M. Shelan
Prof. Dr. med. D. Aebersold
Prof. Dr. med. P. Ghadjar
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 4/2020
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-020-01591-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Frühe Salvage-Bestrahlung der Prostataloge scheint gleichwertig zu sein mit der direkten adjuvanten Bestrahlung bei Prostatakrebspatienten nach radikaler Prostatektomie

Auszug

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 4/2020

Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors

Intraoperative radiotherapy for breast cancer treatment efficiently targets the tumor bed preventing breast adipose stromal cell outgrowth

Provider decision regret—a useful method for analysis of palliative thoracic re-irradiation for lung cancer?

Hybrid planning techniques for hypofractionated whole-breast irradiation using flattening filter-free beams

Correction to: Timing of thoracic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer: a parallel comparison of two prospective studies

Klinische Implikationen der PORTEC-3-Studie zur Behandlung des Hochrisikoendometriumkarzinoms